{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:45Z","timestamp":1792783425091,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","award":["Funding of the writing of the manuscript"],"award-info":[{"award-number":["Funding of the writing of the manuscript"]}],"id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SEIOMM","award":["Funding of the writing of the manuscript"],"award-info":[{"award-number":["Funding of the writing of the manuscript"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04256-1","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:56:44Z","timestamp":1771354604000},"page":"3059-3074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-2652","authenticated-orcid":false,"given":"Carmen","family":"Beato-Zambrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-1859","authenticated-orcid":false,"given":"Xavier","family":"Nogues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7838-967X","authenticated-orcid":false,"given":"Natalia","family":"Ram\u00edrez-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1799-9048","authenticated-orcid":false,"given":"Mar\u00eda Soledad","family":"Librizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-5428","authenticated-orcid":false,"given":"I\u00f1igo","family":"Etxebarria Foronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-9572","authenticated-orcid":false,"given":"Fernando","family":"Henao-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1331","authenticated-orcid":false,"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-8079","authenticated-orcid":false,"given":"Ibon","family":"Gurruchaga Sot\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9498-5979","authenticated-orcid":false,"given":"Guillermo","family":"Mart\u00ednez-D\u00edaz-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4256_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-025-01362-0","volume":"116","author":"M Teissonni\u00e8re","year":"2025","unstructured":"Teissonni\u00e8re M, Point M, Biver E, Hadji P, Bonnelye E, Ebeling PR, et al. Bone effects of anti-cancer treatments in 2024. Calcif Tissue Int. 2025;116:54. https:\/\/doi.org\/10.1007\/s00223-025-01362-0.","journal-title":"Calcif Tissue Int"},{"key":"4256_CR2","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00198-022-06542-4","volume":"33","author":"C Ye","year":"2022","unstructured":"Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, et al. Fractures and long-term mortality in cancer patients: a population-based cohort study. Osteoporos Int. 2022;33:2629\u201335. https:\/\/doi.org\/10.1007\/s00198-022-06542-4.","journal-title":"Osteoporos Int"},{"key":"4256_CR3","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31:1650\u201363. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019.","journal-title":"Ann Oncol"},{"key":"4256_CR4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83082","volume":"17","author":"E Kourtis","year":"2025","unstructured":"Kourtis E, Zygogiannis K, Fanourgiakis I, Koulalis D, Stathopoulos KD. Understanding and managing fracture risk in patients with cancer: a literature review. Cureus. 2025;17:e83082. https:\/\/doi.org\/10.7759\/cureus.83082.","journal-title":"Cureus"},{"key":"4256_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s002239900240","volume":"60","author":"S Casta\u00f1eda","year":"1997","unstructured":"Casta\u00f1eda S, Carmona L, Carvajal I, Arranz R, D\u00edaz A, Garc\u00eda-Vadillo A. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int. 1997;60:343\u20137. https:\/\/doi.org\/10.1007\/s002239900240.","journal-title":"Calcif Tissue Int"},{"key":"4256_CR6","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","volume":"24","author":"R Rizzoli","year":"2013","unstructured":"Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, et al. Cancer-associated bone disease. Osteoporos Int. 2013;24:2929\u201353. https:\/\/doi.org\/10.1007\/s00198-013-2530-3.","journal-title":"Osteoporos Int"},{"key":"4256_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3857\/roj.2023.00969","volume":"42","author":"L Berk","year":"2024","unstructured":"Berk L. The effects of high-dose radiation therapy on bone: a scoping review. Radiat Oncol J. 2024;42:95\u2013103. https:\/\/doi.org\/10.3857\/roj.2023.00969.","journal-title":"Radiat Oncol J"},{"key":"4256_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001.","journal-title":"J Bone Oncol"},{"key":"4256_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100667","volume":"51","author":"N Damaj","year":"2025","unstructured":"Damaj N, Najdi T, Seif S, Nakouzi N, Kattan J. Zoledronic acid in metastatic castrate-sensitive prostate cancer: a state-of-the-art review. J Bone Oncol. 2025;51:100667. https:\/\/doi.org\/10.1016\/j.jbo.2025.100667.","journal-title":"J Bone Oncol"},{"key":"4256_CR10","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s12094-022-02872-1","volume":"24","author":"S Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda S, Casas A, Gonz\u00e1lez-Del-Alba A, Mart\u00ednez-D\u00edaz-Guerra G, Nogu\u00e9s X, Ojeda Thies C, et al. Bone loss induced by cancer treatments in breast and prostate cancer patients. Clin Transl Oncol. 2022;24:2090\u2013106. https:\/\/doi.org\/10.1007\/s12094-022-02872-1.","journal-title":"Clin Transl Oncol"},{"key":"4256_CR11","doi-asserted-by":"publisher","DOI":"10.2217\/bmt-2020-0012","author":"CL Shapiro","year":"2020","unstructured":"Shapiro CL. Management of osteoporosis in women with breast cancer. Breast Cancer Manag. 2020. https:\/\/doi.org\/10.2217\/bmt-2020-0012.","journal-title":"Breast Cancer Manag"},{"key":"4256_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2024-2956","volume":"84","author":"GK Raut","year":"2024","unstructured":"Raut GK, Malachowski T, Holt T, Oliveira R, Luo X, Faget D, et al. Abstract 2956: chemotherapy-induced adipocyte senescence triggers bone loss through osteoclast activation. Cancer Res. 2024;84:2956. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-2956.","journal-title":"Cancer Res"},{"key":"4256_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/jbmr.3978","volume":"35","author":"A Chandra","year":"2020","unstructured":"Chandra A, Lagnado AB, Farr JN, Monroe DG, Park S, Hachfeld C, et al. Targeted reduction of senescent cell burden alleviates focal radiotherapy\u2010related bone loss. J Bone Miner Res. 2020;35:1119\u201331. https:\/\/doi.org\/10.1002\/jbmr.3978.","journal-title":"J Bone Miner Res"},{"key":"4256_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jbmr.4537","volume":"37","author":"A Chandra","year":"2022","unstructured":"Chandra A, Lagnado AB, Farr JN, Schleusner M, Monroe DG, Saul D, et al. Bone marrow adiposity in models of radiation\u2010 and aging\u2010related bone loss is dependent on cellular senescence. J Bone Miner Res. 2022;37:997\u20131011. https:\/\/doi.org\/10.1002\/jbmr.4537.","journal-title":"J Bone Miner Res"},{"key":"4256_CR15","doi-asserted-by":"publisher","DOI":"10.20960\/RevOsteoporosMetabMiner.00054","author":"M Tejada-Romero","year":"2024","unstructured":"Tejada-Romero M, Murias-Henr\u00edquez C, Rodr\u00edguez-Abreu D, Rosa-Fern\u00e1ndez F, Su\u00e1rez-Ram\u00edrez N, Rosales A, et al. Alteration of bone quality and prevalence of fragility fractures in patients with breast cancer treated with aromatase inhibitors A case-control study. Rev Osteoporos Metab Miner. 2024. https:\/\/doi.org\/10.20960\/RevOsteoporosMetabMiner.00054.","journal-title":"Rev Osteoporos Metab Miner"},{"key":"4256_CR16","doi-asserted-by":"publisher","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN Task Force report: Bone health in cancer care. . J Natl Compr Canc Netw. 2013;11 Suppl 3:S1-50; quiz S51. https:\/\/doi.org\/10.6004\/jnccn.2013.0215. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.2.2013 and V.3.2013. \u00a9 National Comprehensive Cancer Network, Inc. 2013. All rights re-served. Accessed December 8, 2025. To view the most recent and complete version of the guide-line, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and dis-claims any responsibility for their application or use in any way.","DOI":"10.6004\/jnccn.2013.0215"},{"key":"4256_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1481241","volume":"14","author":"R Ronghe","year":"2024","unstructured":"Ronghe R, Tavares AAS. The skeleton: an overlooked regulator of systemic glucose metabolism in cancer? Front Oncol. 2024;14:1481241. https:\/\/doi.org\/10.3389\/fonc.2024.1481241.","journal-title":"Front Oncol"},{"key":"4256_CR18","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/jco.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37:2916\u201346. https:\/\/doi.org\/10.1200\/jco.19.01696.","journal-title":"J Clin Oncol"},{"key":"4256_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-022-06631-4","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Leslie WD. Fracture risk and assessment in adults with cancer. Osteoporos Int. 2023;34:449\u201366. https:\/\/doi.org\/10.1007\/s00198-022-06631-4.","journal-title":"Osteoporos Int"},{"key":"4256_CR20","unstructured":"Osteoporosis Research Ltd. FRAX calculation tool, https:\/\/www.fraxplus.org; 2008. Accessed 25 Aug 2025"},{"key":"4256_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","volume":"34","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, et al. Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. J Bone Miner Res. 2019;34:1428\u201335. https:\/\/doi.org\/10.1002\/jbmr.3726.","journal-title":"J Bone Miner Res"},{"key":"4256_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355. https:\/\/doi.org\/10.1016\/j.jbo.2021.100355.","journal-title":"J Bone Oncol"},{"key":"4256_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01185-8","volume":"17","author":"A Sharqawi","year":"2022","unstructured":"Sharqawi A, Hewitt K, Alexander C, El-Sakka AI, Lee L. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX\u00ae) enhance stratification and targeted management? Arch Osteoporos. 2022;17:143. https:\/\/doi.org\/10.1007\/s11657-022-01185-8.","journal-title":"Arch Osteoporos"},{"key":"4256_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01659-3","author":"Q Huang","year":"2024","unstructured":"Huang Q, Mitchell C, Theodoulou E, Lee ACK, Brown J. Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework. J Cancer Surviv. 2024. https:\/\/doi.org\/10.1007\/s11764-024-01659-3.","journal-title":"J Cancer Surviv."},{"key":"4256_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/jco.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. J Clin Oncol. 2020;38:1736\u201343. https:\/\/doi.org\/10.1200\/jco.19.03148.","journal-title":"J Clin Oncol"},{"key":"4256_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-020-05804-3","volume":"32","author":"WF Lems","year":"2021","unstructured":"Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC, et al. Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int. 2021;32:399\u2013411. https:\/\/doi.org\/10.1007\/s00198-020-05804-3.","journal-title":"Osteoporos Int"},{"key":"4256_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging10100244","volume":"10","author":"KH Miao","year":"2024","unstructured":"Miao KH, Miao JH, Belani P, Dayan E, Carlon TA, Cengiz TB, et al. Radiological diagnosis and advances in imaging of vertebral compression fractures. J Imaging. 2024;10:244. https:\/\/doi.org\/10.3390\/jimaging10100244.","journal-title":"J Imaging"},{"key":"4256_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9265259","volume":"2017","author":"A Terakado","year":"2017","unstructured":"Terakado A, Orita S, Inage K, Kubota G, Kanzaki T, Mori H, et al. A clinical prospective observational cohort study on the prevalence and primary diagnostic accuracy of occult vertebral fractures in aged women with acute lower back pain using magnetic resonance imaging. Pain Res Manag. 2017;2017:9265259. https:\/\/doi.org\/10.1155\/2017\/9265259.","journal-title":"Pain Res Manag"},{"key":"4256_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2023.101452","volume":"27","author":"H Goel","year":"2024","unstructured":"Goel H, Binkley N, Boggild M, Chan WP, Leslie WD, McCloskey E, et al. Clinical use of trabecular bone score: the 2023 ISCD official positions. J Clin Densitom. 2024;27:101452. https:\/\/doi.org\/10.1016\/j.jocd.2023.101452.","journal-title":"J Clin Densitom"},{"key":"4256_CR30","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1002\/cam4.3200","volume":"9","author":"F Hawkins Carranza","year":"2020","unstructured":"Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Dom\u00ednguez M, Mart\u00edn-Arriscado Arroba C, L\u00f3pez \u00c1lvarez B, Allo Miguel G, et al. Trabecular bone deterioration in differentiated thyroid cancer: impact of long-term TSH suppressive therapy. Cancer Med. 2020;9:5746\u201355. https:\/\/doi.org\/10.1002\/cam4.3200.","journal-title":"Cancer Med"},{"key":"4256_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00198-020-05734-0","volume":"32","author":"NE Lane","year":"2021","unstructured":"Lane NE, Saag K, O\u2019Neill TJ, Manion M, Shah R, Klause U, et al. Real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporos Int. 2021;32:831\u201340. https:\/\/doi.org\/10.1007\/s00198-020-05734-0.","journal-title":"Osteoporos Int."},{"key":"4256_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2023","unstructured":"Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone turnover markers: basic biology to clinical applications. Endocr Rev. 2023;44:417\u201373. https:\/\/doi.org\/10.1210\/endrev\/bnac031.","journal-title":"Endocr Rev"},{"key":"4256_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol. 2020;25:100311. https:\/\/doi.org\/10.1016\/j.jbo.2020.100311.","journal-title":"J Bone Oncol"},{"key":"4256_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53\u20138. https:\/\/doi.org\/10.1210\/jc.2010-2704.","journal-title":"J Clin Endocrinol Metab"},{"key":"4256_CR35","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1002\/cncr.35275","volume":"130","author":"LJ Peppone","year":"2024","unstructured":"Peppone LJ, Kleckner AS, Fung C, Puzas JE, Reschke JE, Culakova E, et al. High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: a phase 2 RCT. Cancer. 2024;130:2538\u201351. https:\/\/doi.org\/10.1002\/cncr.35275.","journal-title":"Cancer"},{"key":"4256_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/nu16050708","volume":"16","author":"C Meyer","year":"2024","unstructured":"Meyer C, Brockmueller A, Buhrmann C, Shakibaei M. Prevention and co-management of breast cancer-related osteoporosis using resveratrol. Nutrients. 2024;16:708. https:\/\/doi.org\/10.3390\/nu16050708.","journal-title":"Nutrients"},{"key":"4256_CR37","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00198-018-4534-5","volume":"29","author":"R Rizzoli","year":"2018","unstructured":"Rizzoli R, Biver E, Bonjour JP, Coxam V, Goltzman D, Kanis JA, et al. Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporos Int. 2018;29:1933\u201348. https:\/\/doi.org\/10.1007\/s00198-018-4534-5.","journal-title":"Osteoporos Int"},{"key":"4256_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2025.105805","volume":"133","author":"H Yang","year":"2025","unstructured":"Yang H, Jiang Y, Luo Y, Qin K, Yang C, Liang D, et al. Associations of protein intake with the risk of fractures: a prospective cohort study of UK biobank participants. Arch Gerontol Geriatr. 2025;133:105805. https:\/\/doi.org\/10.1016\/j.archger.2025.105805.","journal-title":"Arch Gerontol Geriatr"},{"key":"4256_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11914-024-00892-0","volume":"22","author":"R Rizzoli","year":"2024","unstructured":"Rizzoli R, Chevalley T. Nutrition and osteoporosis prevention. Curr Osteoporos Rep. 2024;22:515\u201322. https:\/\/doi.org\/10.1007\/s11914-024-00892-0.","journal-title":"Curr Osteoporos Rep"},{"key":"4256_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11657-025-01575-8","volume":"20","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Islam T, Islam MS, Danishuddin Haque MA. Clinical insights into the role of smoking, diabetes, and rheumatoid arthritis in osteoporotic fractures. Arch Osteoporos. 2025;20:87. https:\/\/doi.org\/10.1007\/s11657-025-01575-8.","journal-title":"Arch Osteoporos"},{"key":"4256_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101758","volume":"36","author":"SL Wilson-Barnes","year":"2022","unstructured":"Wilson-Barnes SL, Lanham-New SA, Lambert H. Modifiable risk factors for bone health & fragility fractures. Best Pract Res Clin Rheumatol. 2022;36:101758. https:\/\/doi.org\/10.1016\/j.berh.2022.101758.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4256_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.afos.2019.09.005","volume":"5","author":"R Coronado-Zarco","year":"2019","unstructured":"Coronado-Zarco R, de Olascoaga-G\u00f3mez Le\u00f3n A, Garc\u00eda-Lara A, Quinza\u00f1os-Fresnedo J, Nava-Bringas TI, Mac\u00edas-Hern\u00e1ndez SI. Nonpharmacological interventions for osteoporosis treatment: systematic review of clinical practice guidelines. Osteoporos Sarcopenia. 2019;5:69\u201377. https:\/\/doi.org\/10.1016\/j.afos.2019.09.005.","journal-title":"Osteoporos Sarcopenia"},{"key":"4256_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40139-020-00209-7","volume":"8","author":"JM Eby","year":"2020","unstructured":"Eby JM, Sharieh F, Callaci JJ. Impact of alcohol on bone health, homeostasis and fracture repair. Curr Pathobiol Rep. 2020;8:75\u201386. https:\/\/doi.org\/10.1007\/s40139-020-00209-7.","journal-title":"Curr Pathobiol Rep"},{"key":"4256_CR44","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2105\/ajph.2016.303336","volume":"106","author":"E Mostofsky","year":"2016","unstructured":"Mostofsky E, Mukamal KJ, Giovannucci EL, Stampfer MJ, Rimm EB. Key findings on alcohol consumption and a variety of health outcomes from the Nurses\u2019 Health Study. Am J Public Health. 2016;106:1586\u201391. https:\/\/doi.org\/10.2105\/ajph.2016.303336.","journal-title":"Am J Public Health"},{"key":"4256_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.drugalcdep.2019.01.025","volume":"197","author":"Z Cheraghi","year":"2019","unstructured":"Cheraghi Z, Doosti-Irani A, Almasi-Hashiani A, Baigi V, Mansournia N, Etminan M, et al. The effect of alcohol on osteoporosis: a systematic review and meta-analysis. Drug Alcohol Depend. 2019;197:197\u2013202. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.025.","journal-title":"Drug Alcohol Depend"},{"key":"4256_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/gl-2020-0524suppl","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association Of Clinical Endocrinologists\/American College Of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update. Endocr Pract. 2020;26:1\u201346. https:\/\/doi.org\/10.4158\/gl-2020-0524suppl.","journal-title":"Endocr Pract"},{"key":"4256_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031515","volume":"19","author":"J Godos","year":"2022","unstructured":"Godos J, Giampieri F, Chisari E, Micek A, Paladino N, Forbes-Hern\u00e1ndez TY, et al. Alcohol consumption, bone mineral density, and risk of osteoporotic fractures: a dose-response meta-analysis. Int J Environ Res Public Health. 2022;19:1515. https:\/\/doi.org\/10.3390\/ijerph19031515.","journal-title":"Int J Environ Res Public Health"},{"key":"4256_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/nu13124499","volume":"13","author":"SK Papadopoulou","year":"2021","unstructured":"Papadopoulou SK, Papadimitriou K, Voulgaridou G, Georgaki E, Tsotidou E, Zantidou O, et al. Exercise and nutrition impact on osteoporosis and sarcopenia-the incidence of osteosarcopenia: a narrative review. Nutrients. 2021;13:4499. https:\/\/doi.org\/10.3390\/nu13124499.","journal-title":"Nutrients"},{"key":"4256_CR49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00198-021-06131-x","volume":"33","author":"GL Rose","year":"2022","unstructured":"Rose GL, Skinner TL, Keating SE, Friedrich NK, Bolam KA. The effects of exercise on the bone health of people with cancer: a systematic review and meta-analysis. Osteoporos Int. 2022;33:327\u201338. https:\/\/doi.org\/10.1007\/s00198-021-06131-x.","journal-title":"Osteoporos Int"},{"key":"4256_CR50","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1249\/mss.0000000000002116","volume":"51","author":"KL Campbell","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51:2375\u201390. https:\/\/doi.org\/10.1249\/mss.0000000000002116.","journal-title":"Med Sci Sports Exerc"},{"key":"4256_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101756","volume":"21","author":"C Cerulli","year":"2024","unstructured":"Cerulli C, Moretti E, Grazioli E, Emerenziani GP, Murri A, Tranchita E, et al. Protective role of exercise on breast cancer-related osteoporosis in women undergoing aromatase inhibitors: a narrative review. Bone Rep. 2024;21:101756. https:\/\/doi.org\/10.1016\/j.bonr.2024.101756.","journal-title":"Bone Rep"},{"key":"4256_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, Carlino F, Giunta EF, Franzese E, Guerrera LP, Di Lauro V, et al. Cancer treatment-induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy. Curr Treat Options Oncol. 2021;22:45. https:\/\/doi.org\/10.1007\/s11864-021-00835-2.","journal-title":"Curr Treat Options Oncol"},{"key":"4256_CR53","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049\u2013102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y.","journal-title":"Osteoporos Int"},{"key":"4256_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25826","volume":"3","author":"ZW Myint","year":"2020","unstructured":"Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2025826. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.25826.","journal-title":"JAMA Netw Open"},{"key":"4256_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-020-05619-2","volume":"29","author":"S Sattar","year":"2021","unstructured":"Sattar S, Haase K, Kuster S, Puts M, Spoelstra S, Bradley C, et al. Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment. Support Care Cancer. 2021;29:21\u201333. https:\/\/doi.org\/10.1007\/s00520-020-05619-2.","journal-title":"Support Care Cancer"},{"key":"4256_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.gerinurse.2024.10.030","volume":"62","author":"H Jing","year":"2025","unstructured":"Jing H, Chen Y, Liang B, Tian Z, Song F, Chen M, et al. Risk factors for falls in older people with pre-frailty: a systematic review and meta-analysis. Geriatr Nurs. 2025;62:272\u20139. https:\/\/doi.org\/10.1016\/j.gerinurse.2024.10.030.","journal-title":"Geriatr Nurs"},{"key":"4256_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.2024.8481","volume":"332","author":"WK Nicholson","year":"2024","unstructured":"Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, et al. Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force recommendation statement. JAMA. 2024;332:51\u20137. https:\/\/doi.org\/10.1001\/jama.2024.8481.","journal-title":"JAMA"},{"key":"4256_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2147\/ijwh.S29101","volume":"4","author":"R Aft","year":"2012","unstructured":"Aft R. Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid. Int J Womens Health. 2012;4:569\u201376. https:\/\/doi.org\/10.2147\/ijwh.S29101.","journal-title":"Int J Womens Health"},{"key":"4256_CR59","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/jco.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820\u20138. https:\/\/doi.org\/10.1200\/jco.2005.02.7102.","journal-title":"J Clin Oncol"},{"key":"4256_CR60","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118:1192\u2013201. https:\/\/doi.org\/10.1002\/cncr.26313.","journal-title":"Cancer"},{"key":"4256_CR61","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/jco.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875\u201382. https:\/\/doi.org\/10.1200\/jco.2008.16.3832.","journal-title":"J Clin Oncol"},{"key":"4256_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/s0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433\u201343. https:\/\/doi.org\/10.1016\/s0140-6736(15)60995-3.","journal-title":"Lancet"},{"key":"4256_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","volume":"94","author":"C Wilson","year":"2018","unstructured":"Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, et al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study. Eur J Cancer. 2018;94:70\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.004.","journal-title":"Eur J Cancer"},{"key":"4256_CR64","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jbmr.3886","volume":"35","author":"M Pineda-Moncus\u00ed","year":"2020","unstructured":"Pineda-Moncus\u00ed M, Garcia-Giralt N, Diez-Perez A, Servitja S, Tusquets I, Prieto-Alhambra D, et al. Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res. 2020;35:291\u20137. https:\/\/doi.org\/10.1002\/jbmr.3886.","journal-title":"J Bone Miner Res"},{"key":"4256_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100694","volume":"53","author":"P Hadji","year":"2025","unstructured":"Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2025;53:100694. https:\/\/doi.org\/10.1016\/j.jbo.2025.100694.","journal-title":"J Bone Oncol"},{"key":"4256_CR66","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27:1917\u201321. https:\/\/doi.org\/10.1007\/s00198-015-3458-6.","journal-title":"Osteoporos Int"},{"key":"4256_CR67","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa756.","journal-title":"J Clin Endocrinol Metab"},{"key":"4256_CR68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","volume":"36","author":"N Laursen","year":"2025","unstructured":"Laursen N, S\u00f8lling AS, Harsl\u00f8f T, Langdahl B. Clinical experience with denosumab discontinuation. Osteoporos Int. 2025;36:435\u201346. https:\/\/doi.org\/10.1007\/s00198-024-07351-7.","journal-title":"Osteoporos Int"},{"key":"4256_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155207080806","volume":"13","author":"K Olson","year":"2007","unstructured":"Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract. 2007;13:223\u20139. https:\/\/doi.org\/10.1177\/1078155207080806.","journal-title":"J Oncol Pharm Pract"},{"key":"4256_CR70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","volume":"65","author":"BA Gartrell","year":"2014","unstructured":"Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-\u03baB ligand inhibitors in patients with advanced prostate cancer. Eur Urol. 2014;65:278\u201386. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.015.","journal-title":"Eur Urol"},{"key":"4256_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-265400","volume":"18","author":"A Alabbasi","year":"2025","unstructured":"Alabbasi A, Moloney DP, Murariu CM, Khan SU. Bisphosphonate beak without the bisphosphonate: atypical femoral fracture with denosumab. BMJ Case Rep. 2025;18:e265400. https:\/\/doi.org\/10.1136\/bcr-2025-265400.","journal-title":"BMJ Case Rep"},{"key":"4256_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s40902-023-00391-9","volume":"45","author":"JY Kang","year":"2023","unstructured":"Kang JY, Kim SY, Lim JS, Kim JY, Jin GY, Lee YJ, et al. Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study. Maxillofac Plast Reconstr Surg. 2023;45:23. https:\/\/doi.org\/10.1186\/s40902-023-00391-9.","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"4256_CR73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/s1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:339\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(18)30862-3.","journal-title":"Lancet Oncol"},{"key":"4256_CR74","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/med.0000000000000287","volume":"23","author":"RA Adler","year":"2016","unstructured":"Adler RA. Bisphosphonates and atypical femoral fractures. Curr Opin Endocrinol Diabetes Obes. 2016;23:430\u20134. https:\/\/doi.org\/10.1097\/med.0000000000000287.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"4256_CR75","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/eje-17-1002","volume":"178","author":"RA Adler","year":"2018","unstructured":"Adler RA. Management of endocrine disease: atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Eur J Endocrinol. 2018;178:R81\u20137. https:\/\/doi.org\/10.1530\/eje-17-1002.","journal-title":"Eur J Endocrinol"},{"key":"4256_CR76","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972\u20138. https:\/\/doi.org\/10.1016\/j.juro.2006.04.078.","journal-title":"J Urol"},{"key":"4256_CR77","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745\u201355. https:\/\/doi.org\/10.1056\/NEJMoa0809003.","journal-title":"N Engl J Med."},{"key":"4256_CR78","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00520-018-4060-1","volume":"26","author":"A Menshawy","year":"2018","unstructured":"Menshawy A, Mattar O, Abdulkarim A, Kasem S, Nasreldin N, Menshawy E, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26:1029\u201338. https:\/\/doi.org\/10.1007\/s00520-018-4060-1.","journal-title":"Support Care Cancer"},{"key":"4256_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013020.pub2","volume":"12","author":"T Jakob","year":"2020","unstructured":"Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, et al. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. Cochrane Database Syst Rev. 2020;12:Cd013020. https:\/\/doi.org\/10.1002\/14651858.CD013020.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4256_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132291","volume":"16","author":"KM Han","year":"2024","unstructured":"Han KM, Kwon MJ, Kim JH, Kim JH, Bang WJ, Choi HG, et al. Association between gastric cancer and osteoporosis: a longitudinal follow-up study using a national health sample cohort. Cancers (Basel). 2024;16:2291. https:\/\/doi.org\/10.3390\/cancers16132291.","journal-title":"Cancers (Basel)"},{"key":"4256_CR81","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12020-024-04140-4","volume":"88","author":"C Aktypis","year":"2025","unstructured":"Aktypis C, Yavropoulou MP, Efstathopoulos E, Polichroniadi D, Poulia KA, Papatheodoridis G, et al. Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine. 2025;88:348\u201358. https:\/\/doi.org\/10.1007\/s12020-024-04140-4.","journal-title":"Endocrine"},{"key":"4256_CR82","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1210\/clinem\/dgab539","volume":"106","author":"EJ Ku","year":"2021","unstructured":"Ku EJ, Yoo WS, Lee EK, Ahn HY, Woo SH, Hong JH, et al. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:3655\u201367. https:\/\/doi.org\/10.1210\/clinem\/dgab539.","journal-title":"J Clin Endocrinol Metab."},{"key":"4256_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043007","volume":"11","author":"D Kwak","year":"2021","unstructured":"Kwak D, Ha J, Won Y, Kwon Y, Park S. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11:e043007. https:\/\/doi.org\/10.1136\/bmjopen-2020-043007.","journal-title":"BMJ Open"},{"key":"4256_CR84","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/jbmr.3407","volume":"33","author":"DW Shin","year":"2018","unstructured":"Shin DW, Suh B, Lim H, Yun JM, Song SO, Park Y. J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. J Bone Miner Res. 2018;33:1037\u201343. https:\/\/doi.org\/10.1002\/jbmr.3407.","journal-title":"J Bone Miner Res"},{"key":"4256_CR85","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2021;36:42\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfaa192.","journal-title":"Nephrol Dial Transplant"},{"key":"4256_CR86","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376\u201384. https:\/\/doi.org\/10.1002\/cncr.22904.","journal-title":"Cancer"},{"key":"4256_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","volume":"14","author":"SM Moe","year":"2007","unstructured":"Moe SM, Dr\u00fceke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14:3\u201312. https:\/\/doi.org\/10.1053\/j.ackd.2006.10.005.","journal-title":"Adv Chronic Kidney Dis"},{"key":"4256_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/mnh.0000000000000585","volume":"29","author":"MJ Damasiewicz","year":"2020","unstructured":"Damasiewicz MJ, Nickolas TL. Bisphosphonate therapy in CKD: the current state of affairs. Curr Opin Nephrol Hypertens. 2020;29:221\u20136. https:\/\/doi.org\/10.1097\/mnh.0000000000000585.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4256_CR89","unstructured":"European Medicines Agency. Summary of Product Characteristics. Zometa, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zometa-epar-product-information_en.pdf; 2009. Accessed 17 Oct 2025."},{"key":"4256_CR90","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/cjn.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7:1713\u201321. https:\/\/doi.org\/10.2215\/cjn.02780312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4256_CR91","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471\u20139. https:\/\/doi.org\/10.1002\/jbmr.1613.","journal-title":"J Bone Miner Res"},{"key":"4256_CR92","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2215\/cjn.03850609","volume":"5","author":"SM Sprague","year":"2010","unstructured":"Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:512\u20138. https:\/\/doi.org\/10.2215\/cjn.03850609.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4256_CR93","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2215\/cjn.09500916","volume":"11","author":"SM Moe","year":"2016","unstructured":"Moe SM, Nickolas TL. Fractures in patients with CKD: time for action. Clin J Am Soc Nephrol. 2016;11:1929\u201331. https:\/\/doi.org\/10.2215\/cjn.09500916.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4256_CR94","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blad\u00e9 J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485\u201393. https:\/\/doi.org\/10.1038\/leu.2008.131.","journal-title":"Leukemia"},{"key":"4256_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, M\u00fcller R, et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 2022;10:207\u201320. https:\/\/doi.org\/10.1016\/s2213-8587(21)00347-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4256_CR96","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007;18:427\u201344. https:\/\/doi.org\/10.1007\/s00198-006-0253-4.","journal-title":"Osteoporos Int"},{"key":"4256_CR97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1210\/jcem.86.1.7139","volume":"86","author":"AV Schwartz","year":"2001","unstructured":"Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32\u20138. https:\/\/doi.org\/10.1210\/jcem.86.1.7139.","journal-title":"J Clin Endocrinol Metab"},{"key":"4256_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00072","volume":"4","author":"M Saito","year":"2013","unstructured":"Saito M, Marumo K. Bone quality in diabetes. Front Endocrinol (Lausanne). 2013;4:72. https:\/\/doi.org\/10.3389\/fendo.2013.00072.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4256_CR99","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67:1471\u201380. https:\/\/doi.org\/10.2337\/dbi18-0002.","journal-title":"Diabetes"},{"key":"4256_CR100","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32\u20139. https:\/\/doi.org\/10.1503\/cmaj.080486.","journal-title":"CMAJ"},{"key":"4256_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44\u201351. https:\/\/doi.org\/10.1210\/jc.2015-1860.","journal-title":"J Clin Endocrinol Metab"},{"key":"4256_CR102","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-019-04968-x","volume":"30","author":"K Hidayat","year":"2019","unstructured":"Hidayat K, Du X, Shi BM. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int. 2019;30:1923\u201340. https:\/\/doi.org\/10.1007\/s00198-019-04968-x.","journal-title":"Osteoporos Int"},{"key":"4256_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3170","volume":"35","author":"X Li","year":"2019","unstructured":"Li X, Li T, Cheng Y, Lu Y, Xue M, Xu L, et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev. 2019;35:e3170. https:\/\/doi.org\/10.1002\/dmrr.3170.","journal-title":"Diabetes Metab Res Rev"},{"key":"4256_CR104","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/obr.12885","volume":"20","author":"K Hidayat","year":"2019","unstructured":"Hidayat K, Du X, Wu MJ, Shi BM. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta-analysis of observational studies. Obes Rev. 2019;20:1494\u2013503. https:\/\/doi.org\/10.1111\/obr.12885.","journal-title":"Obes Rev"},{"key":"4256_CR105","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018;124:1111\u201321. https:\/\/doi.org\/10.1002\/cncr.31200.","journal-title":"Cancer"},{"key":"4256_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00223-005-0068-x","volume":"77","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 2005;77:139\u201344. https:\/\/doi.org\/10.1007\/s00223-005-0068-x.","journal-title":"Calcif Tissue Int"},{"key":"4256_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000398","volume":"3","author":"C Ye","year":"2024","unstructured":"Ye C, Zhao B, Leslie WD, Ruiz JI, Zhao H, Abdel-Wahab N, et al. Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors. BMJ Oncol. 2024;3:e000398. https:\/\/doi.org\/10.1136\/bmjonc-2024-000398.","journal-title":"BMJ Oncol"},{"key":"4256_CR108","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","volume":"149","author":"DM Filippini","year":"2021","unstructured":"Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, et al. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis. Int J Cancer. 2021;149:675\u201383. https:\/\/doi.org\/10.1002\/ijc.33592.","journal-title":"Int J Cancer"},{"key":"4256_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405.","journal-title":"J Bone Miner Res"},{"key":"4256_CR110","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022;80:920\u201343. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008.","journal-title":"J Oral Maxillofac Surg"},{"key":"4256_CR111","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.eprac.2025.02.016","volume":"31","author":"DS Ali","year":"2025","unstructured":"Ali DS, Khan AA, Morrison A, Tetradis S, Mirza RD, El Rabbany M, et al. Antiresorptive therapy to reduce fracture risk and effects on dental implant outcomes in patients with osteoporosis: a systematic review and Osteonecrosis of the Jaw Taskforce consensus statement. Endocr Pract. 2025;31:686\u201398. https:\/\/doi.org\/10.1016\/j.eprac.2025.02.016.","journal-title":"Endocr Pract"},{"key":"4256_CR112","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/jco.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol. 2019;37:2270\u201390. https:\/\/doi.org\/10.1200\/jco.19.01186.","journal-title":"J Clin Oncol"},{"key":"4256_CR113","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","volume":"107","author":"AD Anastasilakis","year":"2022","unstructured":"Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab. 2022;107:1441\u201360. https:\/\/doi.org\/10.1210\/clinem\/dgab888.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04256-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:24Z","timestamp":1784975364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04256-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":113,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4256"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04256-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carmen Beato-Zambrano has received honoraria for lectures and participation on advisory boards from AstraZeneca, Bristol Myers Squibb, Laboratorios Farmac\u00e9uticos ROVI and LEO Pharma; and travel support from Amgen. Xavier Nogu\u00e9s has received honoraria for lectures and participation on advisory boards from Amgen, UCB, Geden-Richter and Theramex. Natalia Ram\u00edrez-Merino has received travel support from F. Hoffmann-La Roche Ltd and Pfizer Inc. Mar\u00eda Soledad Librizzi has received travel support from UCB Pharma and Amgen and has received honoraria for lectures from Theramex, UCB Pharma and Amgen. Santos Casta\u00f1eda has received travel support from Amgen, Eli Lilly and Company, Pfizer Inc. and UCB Pharma; and fees for participation on advisory boards for Amgen, Gedeon Richter Plc, Sandoz, STADA Arzneimittel AG and UCB Pharma. I\u00f1igo Etxebarria Foronda declares that he has no conflicts of interest associated with this work\n                      .\n                      Fernando Henao-Carrasco has received fees for participating in advisory boards from AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, Lilly, and Roche. Javier Puente has received research grants from F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., Pfizer Inc. and Merck KGaA (Darmstadt, Germany); honoraria for lectures and participation on advisory boards from AstraZeneca, Bayer AG, Eisai Co., Ltd., Ipsen, Janssen (Johnson & Johnson), Novartis Pharma AG, MSD (Merck & Co., Inc., Rahway, New Jersey, USA), Pfizer Inc., Gilead Sciences, Inc., Bristol Myers Squibb, Laboratorios Farmac\u00e9uticos ROVI and Merck KGaA (Darmstadt, Germany); and travel support from Janssen, Merck KGaA (Darmstadt, Germany), Ipsen and Pfizer Inc. Ibon Gurruchaga Sot\u00e9s has received honoraria for lectures from GlaxoSmithKline, Bristol Myers Squibb and MSD (Merck & Co., Inc., Rahway, New Jersey, USA); and travel support from Merck KGaA (Darmstadt, Germany), Bristol Myers Squibb, MSD (Merck & Co., Inc., Rahway, New Jersey, USA), Pierre Fabre and Ipsen. Guillermo Mart\u00ednez-D\u00edaz-Guerra has received travel support from UCB Pharma, Amgen and Theramex; and fees for participation on advisory boards for UCB Pharma, Amgen and Italfarmaco S.p.A.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review of previously published studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}